BlossomHill Therapeutics, Inc. (NASDAQ:BLSM – Get Free Report) CFO Jason Keyes bought 700 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were bought at an average cost of $16.00 per share, with a total value of $11,200.00. Following the purchase, the chief financial officer directly owned 700 shares of the company’s stock, valued at approximately $11,200. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.
BlossomHill Therapeutics Stock Performance
BLSM opened at $15.99 on Tuesday. BlossomHill Therapeutics, Inc. has a twelve month low of $15.25 and a twelve month high of $17.25.
See Also
- Five stocks we like better than BlossomHill Therapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
